NMRA vs ORCL · $283.5M cap vs P/E 31, rev $67.36B
Neumora Therapeutics, Inc. (NMRA) versus Oracle Corporation (ORCL) — a side-by-side from cached financials, not a winner call.
Neumora Therapeutics, Inc. (NMRA) is a biotechnology company listed on NASDAQ.
Oracle Corporation (ORCL) is a software - infrastructure company listed on NYSE. It is led by Safra Catz.
NMRA does not have a complete income-statement cache yet.
Latest reported ORCL revenue for 2026-05-31 was $67.36B. Net income was $17.09B. Revenue was up 17.3% from 2025-05-31 to 2026-05-31. ORCL currently screens at market cap $527.84B and trailing P/E 31.4.
NMRA currently screens at market cap $283.5M. ORCL currently screens at market cap $527.84B and trailing P/E 31.4.
Not investment advice. Open the NMRA and ORCL stock pages for the full models.
Not investment advice.